# Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

Source: https://onco.cc/trials/nct06353997/  
OnCo record `nct06353997` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of pembrolizumab and INBRX-106 in triple-negative breast cancer, run by Providence Health & Services, now recruiting.

## Summary

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients is a phase 2, interventional study registered as NCT06353997 by Providence Health & Services, with a registry enrolment figure of 12 participants, started 2024-09-05 and due to reach its primary completion in 2027-06. Interventions recorded: Pembrolizumab; INBRX-106. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Patients must have histologically confirmed TNBC (ER/PR ≤ 10% allowed, HER2- as defined by ASCO guidelines)". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06353997
- Phase: 2
- Setting: A Phase II, Single-arm, Multi-center, Open-label Study of Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as an Induction Immunotherapy for Stage II/III TNBC Patients
- Sponsor: Providence Health & Services
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT06353997: https://clinicaltrials.gov/study/NCT06353997

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [INBRX-106](https://onco.cc/drugs/inbrx-106/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06353997.json